Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-center, 3-month, Observational Study to Evaluate the Effectiveness and Safety of Lemborexant in Chinese Patients With Insomnia in Real World Setting

Next Previous
Trial Profile

A Prospective, Multi-center, 3-month, Observational Study to Evaluate the Effectiveness and Safety of Lemborexant in Chinese Patients With Insomnia in Real World Setting

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lemborexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Acronyms PROEM

Most Recent Events

  • 03 Sep 2025 According to the Eisai Co Ltd Media Release, data from this study will be presented at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10.
  • 30 Jul 2024 Status changed from not yet recruiting to recruiting.
  • 31 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top